Cited by 582Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsInflammatory Biomarkers in Disease Prognosis

The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.

The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate

Open access

Caine, Graham J, Stonelake, Paul S, Lip, Gregory Y H, Kehoe, Sean T·2002·Neoplasia

DOI 10.1038/sj.neo.7900263PMC PMC1550339

Open this paper in CoChat — free account

Abstract

A hypercoagulable or prothrombotic state of malignancy occurs due to the ability of tumor cells to activate the coagulation system. It has been estimated that hypercoagulation accounts for a significant percentage of mortality and morbidity in cancer patients. Prothrombotic factors in cancer include the ability of tumor cells to produce and secrete procoagulant/fibrinolytic substances and inflammatory cytokines, and the physical interaction between tumor cell and blood (monocytes, platelets, neutrophils) or vascular cells. Other mechanisms of thrombus promotion in malignancy include nonspecific factors such as the generation of acute phase reactants and necrosis (i.e., inflammation), abnormal protein metabolism (i.e., paraproteinemia), and hemodynamic compromise (i.e., stasis). In addition, anticancer therapy (i.e., surgery/chemotherapy/hormone therapy) may significantly increase the risk of thromboembolic events by similar mechanisms, e.g., procoagulant release, endothelial damage, or stimulation of tissue factor production by host cells. However, not all of the mechanisms for the production of a hypercoagulable state of cancer are entirely understood. In this review, we attempt to describe what is currently accepted about the pathophysiology of the hypercoagulable state of cancer. We also discuss whether or not to screen patients with idiopathic deep venous thrombosis for an underlying malignancy, and whether this would be beneficial to patients. It is hoped that a better understanding of these mechanisms will ultimately lead to the development of more targeted treatment to prevent thromboembolic complications in cancer patients. It is also hoped that antithrombotic strategies may also have a positive effect on the process of tumor growth and dissemination.

Integrity signals

Registry

Crossref · 10.1038/sj.neo.7900263

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,368
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
Fisher, B., Costantino, J., Redmond, C. K., POISSON, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,466
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.
Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Fiers, W. C., Cotran, R. S., & Gimbrone, M. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4533 · Cited by 1,059
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
Levitan, N. I., Dowlati, A., Remick, S. C., Tahsildar, H. I., Sivinski, L. D., Beyth, R. J., & Rimm, A. A. (1999) · Medicine · doi:10.1097/00005792-199909000-00001 · Cited by 891
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.
Clauss, M. A., Gerlach, M. L., Gerlach, H., Brett, J., Wang, F., Familletti, P. C., Pan, Y.-C. E., Olander, J. V., Connolly, D. T., & Stern, D. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.6.1535 · Cited by 831
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
Hull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Trowbridge, A. A., Elliott, C. G., Lerner, R. G., Hall, J. H., Sparling, T. G., Brettell, H. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261502 · Cited by 689
Activation of blood coagulation in cancer: Trousseau's syndrome revisited
Rickles, F., & Edwards, R. (1983) · Blood · doi:10.1182/blood.v62.1.14.bloodjournal62114 · Cited by 680
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
Prandoni, P., Lensing, A. W. A., Buller, H. R., Cogo, A., Prins, M. H., Cattelan, A. M., Cuppini, S., Noventa, F., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210153271604 · Cited by 671
Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone
Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C. C., & Taylor, S. (1983) · Science · doi:10.1126/science.6192498 · Cited by 619

Show all 125 references

Sorted by citations

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citation
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,294
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke‐Pearson, D. L., Flowers, C. R., Jahanzeb, M., Kakkar, A. K., Kuderer, N. M., Levine, M. N., Liebman, H. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 942
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation
Andrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 593
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 564
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 465
Risk factors for venous and arterial thrombosis.
Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011) · PubMed Central · doi:10.2450/2010.0066-10 · Cited by 469
New insights into the mechanisms of venous thrombosis
Mackman, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60229 · Cited by 449
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
Ay, C., Simanek, R., Vormittag, R., Dunkler, D., Alguel, G., Koder, S., Kornek, G. V., Marosi, C., Wagner, O. F., Zielinski, C. C., et al. (2008) · Blood · doi:10.1182/blood-2008-02-142422 · Cited by 420
Venous thromboembolism and prognosis in cancer
Khorana, A. A. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.12.023 · Cited by 413
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Chemotherapy-induced thrombosis
Haddad, T. C., & Greeno, E. W. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2005.10.015 · Cited by 359
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. H. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 331
Association between incident cancer and subsequent stroke
Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Elkind, M. S. V., Panageas, K. S., & DeAngelis, L. M. (2014) · Annals of Neurology · doi:10.1002/ana.24325 · Cited by 258
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Breitbach, C. J., Arulanandam, R., Silva, N. D., Thorne, S. H., Patt, R. H., Daneshmand, M., Moon, A., Ilkow, C. S., Burke, J., Hwang, T.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2687 · Cited by 258
The prothrombotic state in cancer: pathogenic mechanisms
Cicco, M. D. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.10.003 · Cited by 238
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, Μ.-A., Lаgopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 252
Cryptogenic Stroke
Yaghi, S. R., Bernstein, R. A., PASSMAN, R. S., Okin, P. M., & Furie, K. L. (2017) · Circulation Research · doi:10.1161/circresaha.116.308447 · Cited by 195
Anticoagulation Strategies in Patients With Cancer
Mosarla, R. C., Vaduganathan, M., Qamar, A., Moslehi, J. J., Piazza, G., & Giugliano, R. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.017 · Cited by 181
Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States
Potts, J. E., Iliescu, C., Lopez‐Mattei, J., Martinez, S. C., Holmvang, L., Ludman, P., de Belder, M., Kwok, C. S., Rashid, M. O., Fischman, D. L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy769 · Cited by 178
Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells
Jackson, J. M., Witek, M. A., Kamande, J. W., & Soper, S. A. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00016b · Cited by 172
Machine learning-based models for the prediction of breast cancer recurrence risk
Zuo, D., Yang, L., Jin, Y. Q., Qi, H., Liu, Y., & Li, R. (2023) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-023-02377-z · Cited by 166
Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism
van der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 157
Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure
Cedervall, J., Zhang, Y., & Olsson, A.-K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3051 · Cited by 146
Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis
Rumbaut, R. E., & Thiagarajan, P. (2010) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00007ed1v01y201002isp004 · Cited by 149
Stroke and Cancer- A Complicated Relationship.
Dearborn, J. L., Urrutia, V., & Zeiler, S. R. (2014) · PubMed · Cited by 137
Death causes in breast cancer patients
Riihimäki, M., Thomsen, H., Brandt, A., Sundquist, J., & Hemminki, K. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr160 · Cited by 136
Extracellular vesicles and particles impact the systemic landscape of cancer
Lucotti, S., Kenific, C. M., Zhang, H., & Lyden, D. C. (2022) · The EMBO Journal · doi:10.15252/embj.2021109288 · Cited by 145
Pulmonary tumor thrombotic microangiopathy: a systematic review
Godbole, R. H., Saggar, R., & Kamangar, N. (2019) · Pulmonary Circulation · doi:10.1177/2045894019851000 · Cited by 123
Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome
Chen, Q., Tong, S., Dewhirst, M. W., & Yuan, F. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1311.3.10 · Cited by 122
Understanding and managing the possible adverse effects associated with bevacizumab
Shord, S. S., Bressler, L. R., Tierney, L. A., Cuéllar, S., & George, A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080455 · Cited by 122
Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy
Shah, M. A., Ilson, D. H., & Kelsen, D. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.81.908 · Cited by 119
Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival
Saadeh, F. A., Norris, L., O’Toole, S. A., & Gleeson, N. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.06.004 · Cited by 113
Coronary Embolism Among ST-Segment–Elevation Myocardial Infarction Patients
Popovic, B., Agrinier, N., Bouchahda, N., Pinelli, S., Maigrat, C. H., Metzdorf, P. A., Selton‐Suty, C., Juillière, Y., & Camenzind, E. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005587 · Cited by 107
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
“Cancer mortality and morbidity are contributed to by a hypercoagulative state of malignancy in patients [31].”
Background
Stroke risk factor, pattern and outcome in patients with cancer
Zhang, Y.-Y., Chan, D. K. Y., Cordato, D. J., Shen, Q., & Sheng, A. Z. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00709.x · Cited by 96
Cryptogenic Subtype Predicts Reduced Survival Among Cancer Patients With Ischemic Stroke
Navi, B. B., Singer, S., Merkler, A. E., Cheng, N. T., Stone, J. B., Kamel, H., Iadecola, C., Elkind, M. S. V., & DeAngelis, L. M. (2014) · Stroke · doi:10.1161/strokeaha.114.005784 · Cited by 96
Preoperative Anemia Predicts Thrombosis and Free Flap Failure in Microvascular Reconstruction
Hill, J. B., Patel, A., Corral, G. A. D., Sexton, K. W., Ehrenfeld, J. M., Guillamondegui, O. D., & Shack, R. B. (2012) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e31823ed606 · Cited by 90
Tumoral pulmonary hypertension
Price, L., Seckl, M. J., Dorfmüller, P., & Wort, S. J. (2019) · European Respiratory Review · doi:10.1183/16000617.0065-2018 · Cited by 90
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice
Nouh, A. M., Hussain, M., Mehta, T., & Yaghi, S. R. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00037 · Cited by 89
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA
Kwok, C. S., Wong, C. W., Kontopantelis, E., Barac, A., Brown, S.-A. N., Velagapudi, P., Hilliard, A. A., Bharadwaj, A. S., Alraies, M. C., Mohamed, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1032 · Cited by 87
Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
Zamagni, E., Brioli, A., Tacchetti, P., Zannetti, B. A., Pantani, L., & Cavo, M. (2011) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1273085 · Cited by 87
Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice
Cedervall, J., Dragomir, A., Saupe, F., Zhang, Y., Ärnlöv, J., Larsson, E., Dimberg, A., Larsson, A. O., & Olsson, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320009 · Cited by 89
Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
Rinde, L. B., Småbrekke, B., Hald, E. M., Brodin, E. E., Njølstad, I., Mathiesen, E. B., Løchen, M., Wilsgaard, T., Brækkan, S. K., Vik, A., et al. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0231-5 · Cited by 85
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke
Navi, B. B., Marshall, R. S., Bobrow, D., Singer, S., Stone, J. B., DeSancho, M. T., & DeAngelis, L. M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4211 · Cited by 84
Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention
Hess, C. N., Roe, M. T., Clare, R. M., Chiswell, K., Kelly, J., Tcheng, J. E., Hagström, E., James, S. K., Khouri, M. G., Hirsch, B. R., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001779 · Cited by 85
The immunoregulatory glycan‐binding protein galectin‐1 triggers human platelet activation
Pacienza, N., Pozner, R. G., Bianco, G. A., D’Atri, L. P., Croci, D. O., Negrotto, S., Malaver, E., Gomez, R. M., Rabinovich, G. A., & Schattner, M. A. (2007) · The FASEB Journal · doi:10.1096/fj.07-9524com · Cited by 81
Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery
Angka, L., Khan, S., Kilgour, M. K., Xu, R. Y., Kennedy, M. A., & Auer, R. C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081787 · Cited by 81
The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen)
Kell, D. B., & Pretorius, E. (2014) · Integrative Biology · doi:10.1039/c4ib00173g · Cited by 81
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.
Ansari, D., Ansari, D., Andersson, R., & Andrén‐Sandberg, Å. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.06.08 · Cited by 78
Mechanism of Tumor-Platelet Communications in Cancer
Dudiki, T., Veleeparambil, M., Zhevlakova, I., Biswas, S., Klein, E. A., Ford, P., Podrez, E. A., & Byzova, T. V. (2023) · Circulation Research · doi:10.1161/circresaha.122.321861 · Cited by 76
Pulmonary tumour thrombotic microangiopathy
Price, L., Wells, A. U., & Wort, S. J. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000297 · Cited by 76
Nanomedicine as an emerging platform for metastatic lung cancer therapy
Landesman‐Milo, D., Ramishetti, S., & Peer, D. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9554-4 · Cited by 74
Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients
Zhu, L., Li, J., Chen, P., Jiang, Q., & Tang, X.-P. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1350-7 · Cited by 73
Coagulopathic complications in breast cancer
Caine, G. J., Stonelake, P. S., Rea, D. W., & Lip, G. Y. H. (2003) · Cancer · doi:10.1002/cncr.11702 · Cited by 73
Self-citation
Risk Factor, Pattern, Etiology and Outcome in Ischemic Stroke Patients with Cancer: A Nested Case-Control Study
Zhang, Y. Y., Cordato, D. J., Shen, Q., Sheng, A. Z., Hung, W. T., & Chan, D. K. Y. (2006) · Cerebrovascular Diseases · doi:10.1159/000097639 · Cited by 70
Sarcomas of the Aorta: A Systematic Review and Pooled Analysis of Published Reports
Rusthoven, C. G., Liu, A. K., Bui, M. M., Schefter, T. E., ELIAS, A. D., Lu, X. J. D., & Gonzalez, R. J. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.07.012 · Cited by 69
Thrombosis in multiple myeloma
Zangari, M., Elice, F., Fink, L. M., & Tricot, G. J. K. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.3.307 · Cited by 68
Silver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible population
Bian, Y., Kim, K., Ngo, T., Kim, I., Bae, O., Lim, K., & Chung, J. (2019) · Particle and Fibre Toxicology · doi:10.1186/s12989-019-0292-6 · Cited by 67
Venous Thromboembolism in Cancer Patients Undergoing Major Surgery
Osborne, N. H., Wakefield, T. W., & Henke, P. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0151-4 · Cited by 68
Hematologic Abnormalities in the Small Animal Cancer Patient
Childress, M. O. (2011) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2011.09.009 · Cited by 72
TGF-β signalling-related markers in cancer patients with bone metastasis
Baselga, J. M., Rothenberg, M. L., Tabernero, J. M., Seoane, J., Daly, T. M., Cleverly, A., Berry, B., Kloeker, S., RAY, C. A., Fill, J. A., et al. (2008) · Biomarkers · doi:10.1080/13547500701676019 · Cited by 66
Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process
Behrenbruch, C., Shembrey, C., Paquet‐Fifield, S., Mølck, C., Cho, H., Michael, M., Thomson, B. N. J., Heriot, A. G., & Hollande, F. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9873-2 · Cited by 66
Cancer-associated ischemic stroke: A retrospective multicentre cohort study
Grazioli, S., Paciaroni, M., Agnelli, G., Acciarresi, M., Alberti, A., D’Amore, C., Caso, V., Venti, M. P., Guasti, L., Ageno, W., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.011 · Cited by 66
SARS-CoV-2 and cancer: Are they really partners in crime?
van Dam, P. A., Huizing, M. T., Mestach, G., Dierckxsens, S., Tjalma, W. A. A., Trinh, X. B., Papadimitriou, K., Altıntaş, S., Vermorken, J. B., Vulsteke, C., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102068 · Cited by 66
Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment
Reitter, E. ‐., Kaider, A., Ay, C., Quehenberger, P., Marosi, C., Zielinski, C. C., & Pabinger, I. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13218 · Cited by 63
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
Musallam, K. M., Dahdaleh, F. S., Shamseddine, A. I., & Taher, A. T. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.09.008 · Cited by 61
Three-Month Outcomes Are Poor in Stroke Patients with Cancer Despite Acute Stroke Treatment
Cutting, S., Wettengel, M., Conners, J., Ouyang, B., & Busl, K. M. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.10.021 · Cited by 61
The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo
Zhang, X., Wang, C., Wang, X., Zhong, T., Zhao, Y., Zhang, W.-Q., Ren, W., Huang, D., Zhang, S., Guo, Y., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79840 · Cited by 60
cC1qR/CR and gC1qR/p33: Observations in cancer
Peerschke, E. I. B., & Ghebrehiwet, B. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.011 · Cited by 59
Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression
Andreasen, E. B., Tranholm, M., Wiinberg, B., Markussen, B., & Kristensen, A. T. (2012) · Acta veterinaria Scandinavica · doi:10.1186/1751-0147-54-3 · Cited by 59
Statins Decrease the Occurrence of Venous Thromboembolism in Patients with Cancer
Khemasuwan, D., DiVietro, M. L., Tangdhanakanond, K., Pomerantz, S. C., & Eiger, G. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.025 · Cited by 58
Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.
Sun, X., & Zhang, H. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-43 · Cited by 58
New diagnosis of cancer and the risk of subsequent cerebrovascular events
Navi, B. B., Howard, G., Howard, V. J., Zhao, H., Judd, S. E., Elkind, M. S. V., Iadecola, C., DeAngelis, L. M., Kamel, H., Okin, P. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005636 · Cited by 57
Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism
Sano, M., Takahashi, R., Ijichi, H., Ishigaki, K., Yamada, T., Miyabayashi, K., Kimura, G., Mizuno, S., Kato, H., Fujiwara, H., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320608 · Cited by 56
The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma
Wu, J., Chan, Y.-T., Lu, Y., Wang, N., & Feng, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21967 · Cited by 56
Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection
Brown, J. A., Sanidad, K. Z., Lucotti, S., Lieber, C. M., Cox, R. M., Ananthanarayanan, A., Basu, S., Chen, J. B., Shan, M., Amir, M., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2105609 · Cited by 56
Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature
Tufano, A., Guida, A., Minno, M. N. D. D., Prisco, D., Cerbone, A. M., & Minno, G. D. (2011) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1273090 · Cited by 55
Progesterone Increases Tissue Factor Gene Expression, Procoagulant Activity, and Invasion in the Breast Cancer Cell Line ZR-75-1
Kato, S., Pinto, M. P., Carvajal, A., Espinoza, N., Monso, C., Sadarangani, A., Villalón, M., Brosens, J. J., WHITE, J. O., Richer, J. K., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0857 · Cited by 55
Endothelial dysfunction: from the particular to the general. Return to the «Old Paradigm»?
Vlasov, T. D., Ивановна, Н. И., & Shimanski, D. A. (2019) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2019-18-2-19-27 · Cited by 54
Hypercoagulable States in Patients with Hepatocellular Carcinoma
Samonakis, D., Κoutroubakis, I. E., Sfiridaki, A., Malliaraki, N. E., Antoniou, P., Romanos, J., & Kouroumalis, E. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000030099.13397.28 · Cited by 54
The Link Between Cancer and Venous Thromboembolism
Kessler, C. M. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181b01b17 · Cited by 54
Thrombosis in ovarian cancer: a case control study
Metcalf, R. L., Fry, D., Swindell, R., McGurk, A., Clamp, A. R., Jayson, G. C., & Hasan, J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.3 · Cited by 54
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis
Ramacciotti, E., Wolosker, N., Puech‐Leão, P., Zerati, A. E., Gusson, P. R., del Giglio, A., & Franco, R. F. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00179-8 · Cited by 54
Reviews The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression
Kołodziejczyk-Czepas, J., & Ponczek, M. B. (2013) · Współczesna Onkologia · doi:10.5114/wo.2013.34611 · Cited by 51
Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution.
Huang, D., Lan, H., Liu, F., Wang, S., Chen, X., Jin, K., & Mou, X. (2015) · Europe PMC (PubMed Central) · Cited by 50
Risk factors for deep vein thrombosis and pulmonary embolism after traumatic injury: A competing risks analysis
Gent, J. V., Calvo, R. Y., Zander, A. L., Olson, E. J., Sise, C. B., Sise, M. J., & Shackford, S. R. (2017) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001652 · Cited by 50
Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients.
Todorova, V. K., Hsu, P.-C., Wei, J. Y., López‐Candales, A., Chen, J. Z., Su, L. J., & Makhoul, I. (2020) · PubMed Central · Cited by 49
Tumour and microparticle tissue factor expression and cancer thrombosis
Date, K. L., Hall, J., Greenman, J., Maraveyas, A., & Madden, L. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.013 · Cited by 49
Preoperative circulating FPR and CCF score are promising biomarkers for predicting clinical outcome of stage II–III colorectal cancer patients
Sun, F., Peng, H.-X., Gao, Q., Li, S., Zhang, J., Chen, Q.-G., Jiang, Y., Zhang, L., Wang, X.-Z., & Ying, H. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167398 · Cited by 47
Harnessing hyaluronic acid-based nanoparticles for combination therapy: A novel approach for suppressing systemic inflammation and to promote antitumor macrophage polarization
Rangasami, V. K., Samanta, S., Parihar, V. S., Asawa, K., Zhu, K., Varghese, O. P., Teramura, Y., Nilsson, B., Hilborn, J. G., Harris, R. A., et al. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117291 · Cited by 47
Prognostic Significance of Troponin Elevation for Long-Term Mortality after Ischemic Stroke
Ahn, S., Lee, J. S., Kim, Y., Kim, B. J., Kim, Y. J., Kang, D., Kim, J. S., & Kwon, S. U. (2017) · Journal of Stroke · doi:10.5853/jos.2016.01942 · Cited by 46
Cancer-Associated Thrombosis
Karimi, M. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010078 · Cited by 46
PROXIMAL DEEP VEIN THROMBOSIS AFTER HIP REPLACEMENT FOR ONCOLOGIC INDICATIONS
Nathan, S. S., Simmons, K. A., Lin, P. P., Hann, L. E., Morris, C. D., Athanasian, E. A., Boland, P. J., & Healey, J. H. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200605000-00017 · Cited by 46
Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal
Ahmed, O., King, N. E., Qureshi, M. A., Choudhry, A. A., Osama, M., Zehner, C. A., Ali, A., Hamzeh, I., Palaskas, N. L., Thompson, K., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae788 · Cited by 45
The potential benefits of low-molecular-weight heparins in cancer patients
Robert, F. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-3 · Cited by 46
Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery
Carrier, M., Altman, A. D., Blais, N., Diamantouros, A., McLeod, D., Moodley, U., Nguyen, C. P., Young, S. W., & Schwenter, F. (2018) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2018.11.046 · Cited by 45
Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis
Cavallari, I., Verolino, G., Romano, S., & Patti, G. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400300 · Cited by 45
Predicting short and long-term mortality after acute ischemic stroke using EHR
Abedi, V., Avula, V., Razavi, S., Bavishi, S., Chaudhary, D. P., Shahjouei, S., Wang, M., Griessenauer, C. J., Li, J., & Zand, R. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117560 · Cited by 45

Authors: Caine, G. J., Stonelake, P. S., Lip, G. Y. H., & Kehoe, S. T.
Affiliations: Birmingham City Hospital (GB)
Birmingham Women's Hospital (GB)
ORCID: Lip, Gregory Y H
Kehoe, Sean T
Venue: Neoplasia
Publisher: Elsevier BV
Published: 2002
Volume: 4
Issue: 6
Pages: 465-473
ISSN: 1476-5586 (ISSN-L)
1522-8002
DOI: 10.1038/sj.neo.7900263
PMC: PMC1550339
OpenAlex: W2120304210
Cited by: 576
References: 125
Citations by year: 2026: 25 · 2025: 45 · 2024: 30 · 2023: 48 · 2022: 43 · 2021: 36 · 2020: 35 · 2019: 47 · 2018: 49 · 2017: 28 · 2016: 27 · 2015: 25 · 2014: 26 · 2013: 13 · 2012: 7
FWCI: 5.03
Type: journal article
Language: en
Open access: gold
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neoplasia (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords: cancer-associated thrombosis, hypercoagulability, procoagulant factors, fibrinolysis, inflammatory cytokines, tissue factor, antithrombotic therapy, venous thromboembolism
MeSH terms: Antineoplastic Agents, Blood Coagulation, Blood Coagulation Factors, Cell Communication, Humans, Neoplasms, Cytokines, Thrombophilia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks